Using ddPCR to Detect Mycoplasma Contamination
The sensitivity of droplet digital PCR helps manufacturers detect Mycoplasma contamination in AAV-based gene therapy products.
The accelerated pace of gene therapies is a sign of enhancements in our understanding of genetics and viral engineering as well as innovation in manufacturing processes. Despite this progress, gene therapy development is not a perfect science, and manufacturers must be careful to monitor the quality of their products before they reach patients. The sensitivity of droplet digital PCR (ddPCR) helps manufacturers detect Mycoplasma contamination in adeno-associated vector-based gene therapy products.
Read this article in Pharmaceutical Technology's Biologics and Sterile Drug Manufacturing May 2021 eBook.
About the author
Mark White, PhD, is associate director, Biopharma Product Marketing, at Bio-Rad Laboratories.
Article Details
Pharmaceutical Technology
eBook: Biologics and Sterile Drug Manufacturing,May 2021
May 2021
Pages: 26–32
Citations
When referring to this article, please cite it as M. White, “Using ddPCR to Detect Mycoplasma Contamination," Pharmaceutical Technology Biologics and Sterile Drug Manufacturing eBook (May 2021).
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
